Anti-leucine rich glioma inactivated 1 protein and anti-N-methyl-D-aspartate receptor encephalitis show distinct patterns of brain glucose metabolism in 18F-fluoro-2-deoxy-d-glucose positron emission tomography

BMC Neurology

Elham Nabavi⁴  Martin Stangel²  Georg Berding⁴  Frank M Bengel⁴  Lilli Geworski¹  Reinhard Dengler²  Rea Rodriguez-Raecke²  Andreas Leffler³  Jörg Ahrens³  Frank Logemann³  Christoph Schrader²  Elke Voss²  Corinna Trebst²  Cathleen Haense⁴  Anna-Lena Boeck²  Said Ben Tayeb²  Peter Raab⁵  Florian Wilke¹  Florian Wegner² 

[1] Department of Medical Physics, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany;Department of Neurology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany;Department of Anaesthesia and Critical Care Medicine, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany;Department of Nuclear Medicine, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany;Institute of Neuroradiology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany

关键词: ¹⁸F-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET);    Brain glucose metabolism;    Autoimmune limbic encephalitis;    Paraneoplastic syndrome;    Anti- N-methyl-D-aspartate (NMDA) receptor antibody;    Anti- leucine rich glioma inactivated 1 protein (LGI1);   

Others  :  796683
DOI  :  10.1186/1471-2377-14-136

 received in 2014-01-15, accepted in 2014-06-17,  发布年份 2014

【 摘 要 】

Background

Pathogenic autoantibodies targeting the recently identified leucine rich glioma inactivated 1 protein and the subunit 1 of the N-methyl-D-aspartate receptor induce autoimmune encephalitis. A comparison of brain metabolic patterns in ¹⁸F-fluoro-2-deoxy-d-glucose positron emission tomography of anti-leucine rich glioma inactivated 1 protein and anti-N-methyl-D-aspartate receptor encephalitis patients has not been performed yet and shall be helpful in differentiating these two most common forms of autoimmune encephalitis.

Methods

The brain ¹⁸F-fluoro-2-deoxy-d-glucose uptake from whole-body positron emission tomography of six anti-N-methyl-D-aspartate receptor encephalitis patients and four patients with anti-leucine rich glioma inactivated 1 protein encephalitis admitted to Hannover Medical School between 2008 and 2012 was retrospectively analyzed and compared to matched controls.

Results

Group analysis of anti-N-methyl-D-aspartate encephalitis patients demonstrated regionally limited hypermetabolism in frontotemporal areas contrasting an extensive hypometabolism in parietal lobes, whereas the anti-leucine rich glioma inactivated 1 protein syndrome was characterized by hypermetabolism in cerebellar, basal ganglia, occipital and precentral areas and minor frontomesial hypometabolism.

Conclusions

This retrospective ¹⁸F-fluoro-2-deoxy-d-glucose positron emission tomography study provides novel evidence for distinct brain metabolic patterns in patients with anti-leucine rich glioma inactivated 1 protein and anti-N-methyl-D-aspartate receptor encephalitis.

【 授权许可】

   
2014 Wegner et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Gultekin SH, Rosenfeld MR, Voltz R, Eichen J, Posner JB, Dalmau J: Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain 2000, 123:1481-1494.
• [2]Graus F, Delattre JY, Antoine JC, Dalmau J, Giometto B, Grisold W, Honnorat J, Smitt PS, Vedeler C, Verschuuren JJ, Vincent A, Voltz R: Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 2004, 75:1135-1140.
• [3]Zuliani L, Graus F, Giometto B, Bien C, Vincent A: Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognition. J Neurol Neurosurg Psychiatry 2012, 83:638-645.
• [4]Rosenfeld MR, Dalmau JO: Paraneoplastic disorders of the CNS and autoimmune synaptic encephalitis. Continuum (Minneap Minn) 2012, 18:366-383.
• [5]Irani SR, Alexander S, Waters P, Kleopa KA, Pettingill P, Zuliani L, Peles E, Buckley C, Lang B, Vincent A: Antibodies to Kv1 potassium channel-complex proteins leucine rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan’s syndrome and acquired neuromyotonia. Brain 2010, 133:2734-2748.
• [6]Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R: Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011, 10:63-74.
• [7]Lancaster E, Martinez-Hernandez E, Dalmau J: Encephalitis and antibodies to synaptic and neuronal cell surface proteins. Neurology 2011, 77:179-189.
• [8]Gold M, Pul R, Bach JP, Stangel M, Dodel R: Pathogenic and physiological autoantibodies in the central nervous system. Immunol Rev 2012, 248:68-86.
• [9]Ohkawa T, Fukata Y, Yamasaki M, Miyazaki T, Yokoi N, Takashima H, Watanabe M, Watanabe O, Fukata M: Autoantibodies to epilepsy-related LGI1 in limbic encephalitis neutralize LGI1-ADAM22 interaction and reduce synaptic AMPA receptors. J Neurosci 2013, 33:18161-18174.
• [10]Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, Dessain SK, Rosenfeld MR, Balice-Gordon R, Lynch DR: Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008, 7:1091-1098.
• [11]Hughes EG, Peng X, Gleichman AJ, Lai M, Zhou L, Tsou R, Parsons TD, Lynch DR, Dalmau J, Balice-Gordon RJ: Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci 2010, 30:5866-5875.
• [12]Manto M, Dalmau J, Didelot A, Rogemond V, Honnorat J: Afferent facilitation of corticomotor responses is increased by IgGs of patients with NMDA-receptor antibodies. J Neurol 2011, 258:27-33.
• [13]Vincent A, Bien CG, Irani SR, Waters P: Autoantibodies associated with diseases of the CNS: new developments and future challenges. Lancet Neurol 2011, 10:759-772.
• [14]Titulaer MJ, McCracken L, Gabilondo I, Armangué T, Glaser C, Iizuka T, Honig LS, Benseler SM, Kawachi I, Martinez-Hernandez E, Aguilar E, Gresa-Arribas N, Ryan-Florance N, Torrents A, Saiz A, Rosenfeld MR, Balice-Gordon R, Graus F, Dalmau J: Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013, 12:157-165.
• [15]Dalmau J, Tüzün E, Wu HY, Masjuan J, Rossi JE, Voloschin A, Baehring JM, Shimazaki H, Koide R, King D, Mason W, Sansing LH, Dichter MA, Rosenfeld MR, Lynch DR: Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007, 61:25-36.
• [16]Irani SR, Bera K, Waters P, Zuliani L, Maxwell S, Zandi MS, Friese MA, Galea I, Kullmann DM, Beeson D, Lang B, Bien CG, Vincent A: N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain 2010, 133:1655-1667.
• [17]Kamaleshwaran KK, Iyer RS, Antony J, Radhakrishnan EK, Shinto A: 18 F-FDG PET/CT findings in voltage-gated potassium channel limbic encephalitis. Clin Nucl Med 2013, 38:392-394.
• [18]Iizuka T, Sakai F, Ide T, Monzen T, Yoshii S, Iigaya M, Suzuki K, Lynch DR, Suzuki N, Hata T, Dalmau J: Anti-NMDA receptor encephalitis in Japan: long-term outcome without tumor removal. Neurology 2008, 70:504-511.
• [19]Maeder-Ingvar M, Prior JO, Irani SR, Yoshii S, Iigaya M, Suzuki K, Lynch DR, Suzuki N, Hata T, Dalmau J: FDG-PET hyperactivity in basal ganglia correlating with clinical course in anti-NDMA-R antibodies encephalitis. J Neurol Neurosurg Psychiatry 2008, 32:235-236.
• [20]Mohr BC, Minoshima S: F-18 fluorodeoxyglucose PET/CT findings in a case of anti-NMDA receptor encephalitis. Clin Nucl Med 2010, 35:461-463.
• [21]Naeije G, de Hemptinne Q, Depondt C, Pandolfo M, Legros B: Acute behavioural change in a young woman evolving towards cerebellar syndrome. Clin Neurol Neurosurg 2010, 112:509-511.
• [22]Morooka M, Kubota K, Minamimoto R, Furuhata M, Abe T, Ito K, Okasaki M, Ishii K, Ishiwata K: 18 F-FDG and 11C-methionine PET/CT findings in a case with anti-NMDA (NR2B) receptor encephalitis. Clin Nucl Med 2012, 37:400-402.
• [23]Leypoldt F, Buchert R, Kleiter I, Marienhagen J, Gelderblom M, Magnus T, Dalmau J, Gerloff C, Lewerenz J: Fluorodeoxyglucose positron emission tomography in anti-N-methyl-D-aspartate receptor encephalitis: distinct pattern of disease. J Neurol Neurosurg Psychiatry 2012, 83:681-686.
• [24]Shin YW, Lee ST, Shin JW, Moon J, Lim JA, Byun JI, Kim TJ, Lee KJ, Kim YS, Park KI, Jung KH, Lee SK, Chu K: VGKC-complex/LGI1-antibody encephalitis: clinical manifestations and response to immunotherapy. J Neuroimmunol 2013, 265:75-81.
• [25]Wandinger KP, Saschenbrecker S, Stoecker W, Dalmau J: Anti-NMDA-receptor encephalitis: a severe, multistage, treatable disorder presenting with psychosis. J Neuroimmunol 2011, 231:86-91.
• [26]Johnson N, Henry C, Fessler AJ, Dalmau J: Anti-NMDA receptor encephalitis causing prolonged nonconvulsive status epilepticus. Neurology 2010, 75:1480-1482.
• [27]Boeck AL, Logemann F, Krauss T, Hussein K, Bültmann E, Trebst C, Stangel M: Ovarectomy despite negative imaging in anti-NMDA receptor encephalitis: effective even late. Case Rep Neurol Med 2013, 2013:843192.
• [28]Irani SR, Stagg CJ, Schott JM, Rosenthal CR, Schneider SA, Pettingill P, Pettingill R, Waters P, Thomas A, Voets NL, Cardoso MJ, Cash DM, Manning EN, Lang B, Smith SJ, Vincent A, Johnson MR: Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype. Brain 2013, 136:3151-3162.
• [29]Alkire MT, Haier RJ, Barker SJ, Shah NK, Wu JC, Kao YJ: Cerebral metabolism during propofol anesthesia in humans studied with positron emission tomography. Anesthesiology 1995, 82:393-403.
• [30]Schlünzen L, Juul N, Hansen KV, Cold GE: Regional cerebral blood flow and glucose metabolism during propofol anaesthesia in healthy subjects studied with positron emission tomography. Acta Anaesthesiol Scand 2012, 56:248-255.
• [31]Baumgartner A, Rauer S, Mader I, Meyer PT: Cerebral FDG-PET and MRI findings in autoimmune limbic encephalitis: correlation with autoantibody types. J Neurol 2013, 260:2744-2753.
• [32]Ances BM, Vitaliani R, Taylor RA, Liebeskind DS, Voloschin A, Houghton DJ, Galetta SL, Dichter M, Alavi A, Rosenfeld MR, Dalmau J: Treatment-responsive limbic encephalitis identified by neuropil antibodies: MRI and PET correlates. Brain 2005, 128:1764-1777.
• [33]Fauser S, Talazko J, Wagner K, Ziyeh S, Jarius S, Vincent A, Schulze-Bonhage A: FDG-PET and MRI in potassium channel antibody-associated non-paraneoplastic limbic encephalitis: correlation with clinical course and neuropsychology. Acta Neurol Scand 2005, 111:338-343.
• [34]Chatzikonstantinou A, Szabo K, Ottomeyer C, Kern R, Hennerici MG: Successive affection of bilateral temporomesial structures in a case of non-paraneoplastic limbic encephalitis demonstrated by serial MRI and FDG-PET. J Neurol 2009, 256:1753-1755.
• [35]Gast H, Schindler K, Z’graggen WJ, Hess CW: Improvement of non-paraneoplastic voltage-gated potassium channel antibody-associated limbic encephalitis without immunosuppressive therapy. Epilepsy Behav 2010, 17:555-557.
• [36]Schulte U, Thumfart JO, Klöcker N, Sailer CA, Bildl W, Biniossek M, Dehn D, Deller T, Eble S, Abbass K, Wangler T, Knaus HG, Fakler B: The epilepsy-linked Lgi1 protein assembles into presynaptic Kv1 channels and inhibits inactivation by Kvbeta1. Neuron 2006, 49:697-706.
• [37]Poza JJ, Saenz A, Martinez-Gil A, Cheron N, Cobo AM, Urtasun M, Martí-Massó JF, Grid D, Beckmann JS, Prud’homme JF, López de Munain A: Autosomal dominant lateral temporal epilepsy: clinical and genetic study of a large Basque pedigree linked to chromosome 10q. Ann Neurol 1999, 45:182-188.
• [38]Morante-Redolat JM, Gorostidi-Pagola A, Piquer-Sirerol S, Sáenz A, Poza JJ, Galán J, Gesk S, Sarafidou T, Mautner VF, Binelli S, Staub E, Hinzmann B, French L, Prud’homme JF, Passarelli D, Scannapieco P, Tassinari CA, Avanzini G, Martí-Massó JF, Kluwe L, Deloukas P, Moschonas NK, Michelucci R, Siebert R, Nobile C, Pérez-Tur J, López de Munain A: Mutations in the LGI1/Epitempin gene on 10q24 cause autosomal dominant lateral temporal epilepsy. Hum Mol Genet 2002, 11:1119-1128.
• [39]Shugaiv E, Leite IM, Sehitoğlu E, Woodhall M, Çavuş F, Waters P, İçöz S, Birişik Ö, Uğurel E, Ulusoy C, Kürtüncü M, Vural B, Vincent A, Akman-Demir G, Tüzün E: Progressive encephalomyelitis with rigidity and myoclonus: a syndrome with diverse clinical features and antibody responses. Eur Neurol 2013, 69:257-262.
• [40]Nakaoku Y, Maki T, Kanazawa K, Matsumoto R, Fukuyama H, Takahashi R, Ikeda A: A case of smoldering anti-leucine rich glioma inactivated 1 (LGI1) antibody-associated limbic encephalitis with faciobrachial dystonic seizure. Rinsho Shinkeigaku 2013, 53:706-711.
• [41]Fisher RE, Patel NP, Lai EC, Schulz PE: Two different 18F-FDG brain metabolic patterns in autoimmune limbic encephalitis. Clin Nucl Med 2012, 37:213-218.
• [42]Prüss H, Höltje M, Maier N, Gomez A, Buchert R, Harms L, Ahnert-Hilger G, Schmitz D, Terborg C, Kopp U, Klingbeil C, Probst C, Kohler S, Schwab JM, Stoecker W, Dalmau J, Wandinger KP: IgA NMDA receptor antibodies are markers of synaptic immunity in slow cognitive impairment. Neurology 2012, 78:1743-1753.